Dynavax (DVAX) Price Target Adjusted to $60 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Dynavax (DVAX) Bullish Stance Reiterated at Jefferies Following R&D Day
December 12, 2014 9:14 AM ESTJefferies analyst Thomas Wei reiterated a Buy rating and $30 price target on Dynavax Technologies (NASDAQ: DVAX) following the company's R&D day where they reiterated the Heplisav timeline (data by YE15) and provided an overview of new development plans for SD-101 for... More
